Skip to main content
Primary Care Respiratory Journal: Journal of the General Practice Airways Group logoLink to Primary Care Respiratory Journal: Journal of the General Practice Airways Group
editorial
. 2009 Aug 18;18(3):216–223. doi: 10.4104/pcrj.2009.00055

Spirometry in primary care case-identification, diagnosis and management of COPD

David Price 1,*, Alan Crockett 2, Mats Arne 3, Bernard Garbe 4, Rupert Jones 5, Alan Kaplan 6, Arnulf Langhammer 7, Sian Williams 8, Barbara Yawn 9
PMCID: PMC6619278  PMID: 19688142

Abstract

Chronic obstructive pulmonary disease (COPD) is an important cause of morbidity and mortality worldwide, yet it remains significantly under-diagnosed. Systematic and opportunistic case-identification efforts in primary care, using questionnaires, careful assessment to identify symptoms, and follow-up spirometry, might improve diagnosis rates and enable earlier detection and management of COPD.

The aims of spirometry performed for case-identification purposes are to exclude those patients with symptoms but normal lung function and identify those who require more complete investigation for COPD, including ‘diagnostic standard’ spirometry. Among patients with a confirmed diagnosis of COPD, spirometry monitoring is useful in identifying those with rapid deterioration in lung function who require further assessment. Spirometry in primary care can also support patient education and may encourage smoking cessation and treatment adherence.

Keywords: chronic obstructive pulmonary disease, spirometry, case-identification, primary care, diagnosis

Full Text

The Full Text of this article is available as a PDF (1.2 MB).

Footnotes

DP either through his role at the University of Aberdeen or personally has received grants, honoraria or educational support from the following pharmaceutical companies as well as the UK NHS R&D programme: 3M Pharmaceuticals, Abbot Laboratories, AstraZeneca, GlaxoSmithKline, Innovata Biomed, Ivax pharmaceuticals Ltd, Merck, Sharpe and Dohme, Medeva, Novartis, Roche, Schering Plough, Yamanouchi. He does not possess any pharmaceutical shares. AJC has no conflict of interest to declare. MA has no conflict of interest to declare.

BG is a salaried Executive Director of Vitalograph (Respiratory disease and services supplier).

RJ has no conflict of interest to declare. AK has no conflict of interest to declare. AL has no conflict of interest to declare.

SW is Executive Officer of the IPCRG that receives associate corporate membership and project support from a number of pharmaceutical companies. She is also a freelance health consultant and has worked for IMPRESS, a joint initiative between the GPIAG and British Thoracic Society that receives grants from a number of pharmaceutical companies. BY has no conflict of interest to declare.


Articles from Primary Care Respiratory Journal: Journal of the General Practice Airways Group are provided here courtesy of Primary Care Respiratory Society UK/Macmillan Publishers Limited

RESOURCES